NAPSR News: According to market analysts, heart failure drug sales are expected to soar

WASHINGTON - Oct. 10, 2014 - PRLog -- According to the Decisions Resources Group, the chronic heart failure market will grow from approximately $2.9 billion in 2013 to $8.9 billion in 2023. Novartis’ breakthrough heart failure therapy LCZ-696 will be the driving force in this market sector, based on superior clinical results achieved from the largest heart failure study ever done, the PARADIGM -HF Study. Most notably, clinical data from the study revealed the drug’s ability to reduce the risk of death from cardiovascular causes by 20%. LCZ696 is administered in the form of a tablet and specifically works by enhancing the protective neurohormonal systems of the heart (NP system) while simultaneously suppressing the harmful system (the RAAS).

Decision Resources Group Analyst Joseph Dwyer, Ph.D stated “LCZ-696 has demonstrated the potential to disrupt the well-established CHF treatment algorithm following favorable results from the PARADIGM-HF study. This exciting new agent represents a step up from past and present agents in development for CHF in that it could replace the standard of care for many CHF patients.”

Based on a report from Pharmacor, other contributors to the market growth for CHF include Novartis’ aliskiren (Tekturna/Rasilez), Bayer’s finerenone (BAY-94-8862), Teva/Mesoblast’s CEP-41750, Celladon’s Mydicar and Bayer’s rivaroxaban (Xarelto). Expected sales from these therapies will amount to $2 billion by 2023.

Amgen and Ono Pharmaceuticals have also come to an agreement to commercialize ivabradine in the United States and Japan for the treatment of chronic heart failure adding to the market growth. Key clinical data revelead ivabradine reduced the primary composite endpoint of cardiovascular death or hospitalization for worsening HF.

In terms of the acute heart failure market, the expected sales generation will amount to more than $2.6 billion by 2023 based on the launch of two novel biologic vasodilators, Novartis’s serelaxin and Cardiorentis’s ularitide.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!
With such industry leaders paving the way with new beneficial therapeutic breakthroughs, they will need both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to sell their product both proficiently and efficiently.

The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/